Results 301 to 310 of about 428,404 (336)
Some of the next articles are maybe not open access.
Current Opinion in Infectious Diseases, 2008
Invasive fungal infections remain a serious complication for critically ill ICU patients. The aim of this article is to review recent efficacy data of newer antifungal agents for the treatment of invasive candidiasis. The influence that recent epidemiological trends, advances in diagnostic testing, and risk prediction methods exert on the optimization ...
Playford, Elliott Geoffrey +2 more
openaire +4 more sources
Invasive fungal infections remain a serious complication for critically ill ICU patients. The aim of this article is to review recent efficacy data of newer antifungal agents for the treatment of invasive candidiasis. The influence that recent epidemiological trends, advances in diagnostic testing, and risk prediction methods exert on the optimization ...
Playford, Elliott Geoffrey +2 more
openaire +4 more sources
Current Opinion in Microbiology, 2022
Fungi have a profound impact on human health, leading to billions of infections and millions of deaths worldwide each year. Exacerbating the public health burden is the continued emergence of drug-resistant fungal pathogens coupled with a dearth of treatment options to combat serious infections.
Nicole, Robbins, Leah E, Cowen
openaire +2 more sources
Fungi have a profound impact on human health, leading to billions of infections and millions of deaths worldwide each year. Exacerbating the public health burden is the continued emergence of drug-resistant fungal pathogens coupled with a dearth of treatment options to combat serious infections.
Nicole, Robbins, Leah E, Cowen
openaire +2 more sources
Antifungal activity of nontraditional antifungal agents
Current Fungal Infection Reports, 2009Invasive fungal infections are becoming increasingly important in the management of critically ill and immunocompromised patients. As organ and stem cell transplantation becomes more prominent and immune therapies are employed for diseases such as rheumatoid arthritis and plaque psoriasis, the population of patients at risk continues to grow.
Craig A. Martin, William R. Judd
openaire +2 more sources
Antifungals and antifungal drug discovery.
2012Abstract This chapter discusses: (1) important clinical aspects of invasive clinical mycoses, i.e., candidosis and aspergillosis; (2) current antifungal therapeutic options for invasive mycoses; (3) antifungal drug resistance; and (4) approaches to antifungal drug discovery, including identification of drug targets.
A. Tegos +8 more
openaire +2 more sources
Ketoconazole and the Antifungals
Otolaryngology–Head and Neck Surgery, 1985A new antifungal agent, ketoconazole, has been added to the drugs available for the treatment of fungal infections. Ketoconazole has been shown to be effective in the treatment of mucocutaneous candidiasis with a reported 97% positive response rate. This drug may be administered orally to outpatients with a low risk of toxicity.
openaire +3 more sources
Journal of the American Academy of Dermatology, 1990
Until two to three decades ago, only a few drugs were available for the treatment of fungal infections. The status of antifungal therapy changed dramatically in the late 1960s with the introduction of newer broader spectrum agents, such as the iodinated trichlorophenols and the imidazoles, that acted by disruption of the fungal cell membrane.
openaire +3 more sources
Until two to three decades ago, only a few drugs were available for the treatment of fungal infections. The status of antifungal therapy changed dramatically in the late 1960s with the introduction of newer broader spectrum agents, such as the iodinated trichlorophenols and the imidazoles, that acted by disruption of the fungal cell membrane.
openaire +3 more sources
Pediatric Clinics of North America, 1983
When the decision to treat a fungal infection is made, there are several antifungal agents available for use. AmB remains the first-line drug in the treatment of most systemic fungal infections. Miconazole should be used to treat patients who cannot tolerate AmB or who are infected with AmB-resistant organisms.
M H, Koldin, G, Medoff
openaire +2 more sources
When the decision to treat a fungal infection is made, there are several antifungal agents available for use. AmB remains the first-line drug in the treatment of most systemic fungal infections. Miconazole should be used to treat patients who cannot tolerate AmB or who are infected with AmB-resistant organisms.
M H, Koldin, G, Medoff
openaire +2 more sources
Medical Journal of Australia, 2007
The four main classes of antifungal drugs are the polyenes, azoles, allylamines and echinocandins. Clinically useful "older" agents include topical azole formulations (for superficial yeast and dermatophyte infections), first-generation triazoles (fluconazole and itraconazole, for a range of superficial and invasive fungal infections), amphotericin B ...
Sharon C A, Chen, Tania C, Sorrell
openaire +2 more sources
The four main classes of antifungal drugs are the polyenes, azoles, allylamines and echinocandins. Clinically useful "older" agents include topical azole formulations (for superficial yeast and dermatophyte infections), first-generation triazoles (fluconazole and itraconazole, for a range of superficial and invasive fungal infections), amphotericin B ...
Sharon C A, Chen, Tania C, Sorrell
openaire +2 more sources
Antifungal Targets and Research into Antifungal Agents [PDF]
, 2014 Systemic infections of fungal origin are an attendant feature in immunodepressed patients. A study conducted in the United States between 1980 and 1989 already showed that nosocomial infections of fungal origin had increased by 40%. The number of species responsible for these infections remains relatively limited: Candida albicans (80%), Aspergillus ...
openaire +1 more source
Applied Microbiology and Biotechnology, 2002
The search for new drugs against fungal infections is a major challenge to current research in mycotic diseases. The present article reviews the current types of antifungal infections, the current scenario of antifungal antibiotics, and the need and approaches to search for newer antifungal antibiotics and antifungal drug targets.
M, Gupte, P, Kulkarni, B N, Ganguli
openaire +2 more sources
The search for new drugs against fungal infections is a major challenge to current research in mycotic diseases. The present article reviews the current types of antifungal infections, the current scenario of antifungal antibiotics, and the need and approaches to search for newer antifungal antibiotics and antifungal drug targets.
M, Gupte, P, Kulkarni, B N, Ganguli
openaire +2 more sources